RA Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

RA Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$859K	Sell	2,387,744 -4,293,563	-64%	-$2.62M	0.01%	83
2026 Q1	$5.56M	Hold	6,681,307	–	–	0.06%	82
2025 Q4	$4.23M	Hold	6,681,307	–	–	0.04%	65
2025 Q3	$13.2M	Hold	6,681,307	–	–	0.16%	49
2025 Q2	$7.28M	Buy	6,681,307 +536,426	+9%	+$552K	0.12%	51
2025 Q1	$5.97M	Hold	6,144,881	–	–	0.1%	75
2024 Q4	$9.09M	Hold	6,144,881	–	–	0.12%	74
2024 Q3	$13M	Hold	6,144,881	–	–	0.15%	63
2024 Q2	$15M	Hold	6,144,881	–	–	0.2%	56
2024 Q1	$39.8M	Hold	6,144,881	–	–	0.51%	46
2023 Q4	$23.7M	Hold	6,144,881	–	–	0.37%	43
2023 Q3	$13.2M	Hold	6,144,881	–	–	0.26%	51
2023 Q2	$18.7M	Hold	6,144,881	–	–	0.35%	44
2023 Q1	$16M	Buy	6,144,881 +1,853,000	+43%	+$5.52M	0.36%	50
2022 Q4	$8.8M	Hold	4,291,881	–	–	0.18%	53
2022 Q3	$19.4M	Hold	4,291,881	–	–	0.41%	51
2022 Q2	$17.6M	Hold	4,291,881	–	–	0.47%	51
2022 Q1	$18.9M	Hold	4,291,881	–	–	0.41%	54
2021 Q4	$51.1M	Hold	4,291,881	–	–	0.9%	31
2021 Q3	$73.6M	Hold	4,291,881	–	–	1.02%	29
2021 Q2	$74.8M	Buy	+4,291,881	New	+$58.8M	1.2%	25

Other funds holding HOWL

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

RA Capital Management's HOWL Position: Q2 2026 in Review

RA Capital Management reduced its Werewolf Therapeutics (HOWL) stake by 64% in Q2 2026, selling an estimated $2.62M and leaving 2,387,744 shares worth $859K. The position accounts for 0.01% of the portfolio, ranked #83.

RA Capital Management first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $74.8M in Q2 2021. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

RA Capital Management held 2,387,744 shares of Werewolf Therapeutics worth $859K as of Q2 2026.
RA Capital Management sold 4,293,563 Werewolf Therapeutics shares in Q2 2026, an estimated $2.62M.
Werewolf Therapeutics made up 0.01% of RA Capital Management's portfolio in Q2 2026, its #83 holding.
RA Capital Management first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
RA Capital Management's Werewolf Therapeutics position peaked at $74.8M in Q2 2021.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.